Compare THCH & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THCH | ENTX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9M | 62.6M |
| IPO Year | 2021 | 2015 |
| Metric | THCH | ENTX |
|---|---|---|
| Price | $2.09 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.9K | ★ 124.9K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.69 | $0.91 |
| 52 Week High | $3.25 | $3.22 |
| Indicator | THCH | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 55.67 |
| Support Level | $1.70 | $1.12 |
| Resistance Level | $2.31 | $1.38 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.87 | 76.67 |
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.